XML 21 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 645 $ 584
Accounts and grants receivable, net 4 25
Prepaid expenses and other current assets 1,804 1,625
Total current assets 2,453 2,234
Restricted cash 50 50
Intangible assets, net 738 870
TOTAL ASSETS 3,241 3,154
Current liabilities:    
Accounts payable and accrued liabilities 1,034 771
Loan due to Juvenescence, net of debt issuance costs, current portion 7,646 7,140
Related party payables, net 141 70
Warrant liability 180
Insurance premium liability and other current liabilities 1,077 986
Total current liabilities 10,078 8,967
Loan due to Juvenescence, net of debt issuance costs, net of current portion 10,478 6,062
TOTAL LIABILITIES 20,556 15,029
Commitments and contingencies (Note 10)
Stockholders’ deficit:    
Preferred stock, $0.0001 par value, 5,000 shares authorized; none issued and outstanding
Common stock, $0.0001 par value, 200,000 and 100,000 shares authorized, respectively; 37,949 and 37,941 shares issued and outstanding, respectively 4 4
Additional paid-in capital 98,994 93,912
Accumulated deficit (116,210) (105,748)
Total AgeX Therapeutics, Inc. stockholders’ deficit (17,212) (11,832)
Noncontrolling interest (103) (43)
Total stockholders’ deficit (17,315) (11,875)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT $ 3,241 $ 3,154